The assessment of care burden and influencing factors on family caregivers for cancer patients

By

Parvizi, M (Parvizi, Murtaza) ; Ay, S (Ay, Semra)

 (provided by Clarivate) 

Source

JOURNAL OF CLINICAL NURSING

Volume

33

Issue

10

Page

3923-3932

DOI

10.1111/jocn.17408

Published

OCT 2024

Early Access

AUG 2024

Indexed

2024-08-25

Document Type

Article

Abstract

BackgroundThe family caregivers as primary caregivers play a crucial role regarding the care of cancer patients. As defined in the literature, the care burden encompasses the negative objective and subjective outcomes including psychological and physical health problems, economic and social issues, deterioration of family relationships and feelings of loss of control that arise from caregiving responsibilities. AimsThis study aims to assess the care burden and to evaluate the associated factors among family caregivers of cancer patients receiving treatment at a state hospital in T & uuml;rkiye. MethodsThis cross-sectional study was conducted with the family caregivers of patients undergoing treatment in the radiation oncology department of a state hospital in T & uuml;rkiye. The study population consisted of 350 individuals, with a participation rate of 80%. Participants were administered a questionnaire concerning determining daily living activities and identifying the caregiving burden through their socio-demographic characteristics. ResultsThe care burden among primary family caregivers while the delivery of health services was severe for 85.1% of them. The average ZBI score of caregivers was 55.92 +/- 14.58. It was clarified that family caregivers' burden was influenced by several factors, including the duration of caregiving, difficulties experienced while caring for the patient, and the negative impact on their daily roles. ConclusionOur study's findings indicate the need for health professionals to support caregivers of cancer patients while over half of the caregivers were identified as having a severe level of caregiving burden. It is important to raise awareness among nurses and the oncology team with a holistic approach. In the delivery of health services, caregivers' needs should be identified first, support mechanisms should be activated and interventions should be made to meet these needs. ImpactThis study's findings highlight the need to identify and problems faced by family members during caregiving. This is important for sustainable and cost-effective holistic care. Reporting MethodThe results of this study are reported based on the guidelines of The Strengthening the Reporting of Observational Studies (cohort, case-control studies, cross-sectional studies) in Epidemiology (STROBE). Implications for practiceOur study's findings indicate the need for health professionals to support caregivers of cancer patients. It is important to raise awareness among nurses and the oncology team with a holistic approach. In the delivery of health services, caregivers' needs should be identified first, support mechanisms should be activated and interventions should be made to meet these needs.

Keywords

Author Keywords

cancer patients caregiver burden family caregivers

Evaluation of pre-treatment F-18 FDG PET/CT according to Mandard classification in locally advanced rectal cancer patients undergoing neoadjuvant chemoradiotherapy

By

Aras, F (Aras, Feray) ; Parvizi, M (Parvizi, Murtaza) ; Nalbant, OA (Nalbant, Olcay Ak) ; Ozkol, V (Ozkol, Volkan) ; Kut, E (Kut, Engin)

 (provided by Clarivate) 

Source

BMC CANCER

Volume

25

Issue

1

DOI

10.1186/s12885-025-14659-y

Article Number

1262

Published

AUG 4 2025

Indexed

2025-08-13

Document Type

Article

Abstract

BackgroundThis study primarily aimed to assess whether baseline [(18)F] fluorodeoxyglucose (FDG) PET/CT metabolic parameters-including SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG)-can predict tumor regression grade (TRG) and survival in patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy (nCRT). In addition, secondary analyses were performed to identify other clinical and pathological variables associated with treatment response and prognosis.MethodsThis retrospective study included patients diagnosed with LARC who underwent nCRT followed by surgical resection between 2014 and 2023. Pre-treatment staging with F-18 FDG PET/CT was performed for all patients. Postoperative pathological response was assessed using the TRG system. Patients were categorized into two groups: complete responders (TRG1) and incomplete responders (TRG2-5). Demographic characteristics, PET/CT metabolic parameters (SUVmax, MTV, TLG), Carcinoembryonic antigen (CEA), Carbohydrate antigen 19 - 9 (CA19-9), and histopathological features (perforation, lymphovascular invasion [LVI], and perineural invasion [PNI]) were compared between the groups. Statistical analyses included chi-square tests, Mann-Whitney U tests, logistic regression models with odds ratios (ORs), and Kaplan-Meier survival analysis.ResultsA total of 151 patients were included. A statistically significant difference was found between TRG1 and TRG2-5 groups regarding family history (p = 0.034), CEA at diagnosis (p = 0.002), Ca19.9 after radiotherapy (p = 0.045), and presence of concurrent chemotherapy (CC) (p = 0.004). Significant differences were also observed in postoperative pathological features, including perforation (p = 0.045), LVI (p = 0.023), PNI (p = 0.031), and post-operative CEA levels (p = 0.001). In terms of outcomes, TRG1 was associated with better survival (p = 0.001), longer disease-free survival (p = 0.001), and overall survival (p = 0.001). Logistic regression identified independent predictors of complete response (TRG1): family history (OR: 5.08, p = 0.027), post-RT CEA (OR: 0.61, p = 0.015), post-op CEA (OR: 1.13, p = 0.012), perforation (OR: 20.93, p = 0.033), LVI (OR: 0.33, p = 0.042), and PNI (OR: 0.49, p = 0.045). Kaplan-Meier analysis demonstrated significantly longer overall survival in patients with TRG1 compared to TRG2-5 (log-rank p = 0.001). Similarly, disease-free survival was significantly better in the TRG1 group (log-rank p = 0.001). In the multivariate Cox regression model, TRG1 (HR: 0.41; 95% CI: 0.26-0.66; p = 0.001), CC (HR: 0.62; 95% CI: 0.39-0.98; p = 0.039), and absence of perforation (HR: 0.51; 95% CI: 0.28-0.95; p = 0.034) were found to be independent predictors of improved survival.ConclusionsBaseline F-18 FDG PET/CT parameters, including SUVmax, MTV, and TLG, were not predictive of TRG or survival in patients with LARC undergoing neoadjuvant chemoradiotherapy. However, clinical and pathological variables such as family history, post-treatment CEA levels, perforation, lymphovascular invasion, and perineural invasion wereMAR 23 2024 significantly associated with TRG1. TRG1, histopathological subtype, perforation, and CC were also found to be independent predictors of survival. These findings suggest that while FDG-PET/CT may have limited utility in predicting treatment response, certain clinical and pathological features remain critical for outcome assessment.

Indexed

2024-05-11

Document Type

Article

Abstract

The epidermal growth factor receptor (EGFR) expression is considered to play an essential role in the pathogenesis of colorectal adenocarcinoma. This study assessed the expression and predictive/prognostic value of EGFR expression in pre -op biopsy and post -op resection specimens in patients receiving neoadjuvant radiotherapy/neoadjuvant chemoradiotherapy (NRT/NCRT). Thirty-four consecutive patients were included in this study. The association between the prognostic features and EGFR immunohistochemical expression was analyzed in pre- (n=34) and post -treatment (n=22) tissue samples in cases with available tissue blocks. Of 34, 23 (67.6%) were men. The median age was 60.50 +/- 10.69 (range, 31-84) years. EGFR expression was detected in 88.2% of biopsy specimens and in 91.2% of surgical specimens. There was only slight agreement between pre -op and post -op EGFR expression scores (kappa value 0.11). There was no significant correlation between pre -op and post -op EGFR expression scores (p>0.05). Although pre -op EGFR positivity and higher pre -op EGFR scores seemed to indicate a worse prognosis, this association between pre -op EGFR expression and overall survival (OS) or disease -specific survival (DSS) did not reach statistical significance (p>0.05). The only case with a post -op EGFR score of three who died of the disease experienced local recurrence and had distant metastasis. In conclusion, EGFR positivity in pre -op biopsy samples seems to be associated with shorter survival, and increased EGFR expression in post -treatment resection specimens predicts aggressive behavior in patients with rectal adenocarcinoma who received NRT/NCRT. However, due to the molecular heterogeneity, EGFR expression status should be evaluated in resection specimens rather than in pre -op biopsy samples for optimal prognosis prediction.

Keywords

Author Keywords

egfradenocarcinomaprognosisneoadjuvant radiotherapyneoadjuvant chemoradiotherapy

Keywords

Author Keywords

Locally advanced rectal cancer Neoadjuvant chemoradiotherapy (18F) FDG PET/CT Mandard classification

The Association of the Epidermal Growth Factor Receptor (EGFR) Immunoexpression With Prognostic Parameters in Adenocarcinoma Patients Receiving Neoadjuvant Treatment

By

Demir, D (Demir, Derya) ; Parvizi, M (Parvizi, Murtaza) ; Pehlivanoglu, B (Pehlivanoglu, Burcin) ; Ergin, E (Ergin, Erhan) ; Ayhan, S (Ayhan, Semin) ; Doganavsargil, B (Doganavsargil, Basak)

 (provided by Clarivate) 

Source

CUREUS JOURNAL OF MEDICAL SCIENCE

Volume

16

Issue

3

DOI

10.7759/cureus.56763

Article Number

e56763

Published

MAR 23 2024

Indexed

2024-05-11

Document Type

Article

Abstract

The epidermal growth factor receptor (EGFR) expression is considered to play an essential role in the pathogenesis of colorectal adenocarcinoma. This study assessed the expression and predictive/prognostic value of EGFR expression in pre -op biopsy and post -op resection specimens in patients receiving neoadjuvant radiotherapy/neoadjuvant chemoradiotherapy (NRT/NCRT). Thirty-four consecutive patients were included in this study. The association between the prognostic features and EGFR immunohistochemical expression was analyzed in pre- (n=34) and post -treatment (n=22) tissue samples in cases with available tissue blocks. Of 34, 23 (67.6%) were men. The median age was 60.50 +/- 10.69 (range, 31-84) years. EGFR expression was detected in 88.2% of biopsy specimens and in 91.2% of surgical specimens. There was only slight agreement between pre -op and post -op EGFR expression scores (kappa value 0.11). There was no significant correlation between pre -op and post -op EGFR expression scores (p>0.05). Although pre -op EGFR positivity and higher pre -op EGFR scores seemed to indicate a worse prognosis, this association between pre -op EGFR expression and overall survival (OS) or disease -specific survival (DSS) did not reach statistical significance (p>0.05). The only case with a post -op EGFR score of three who died of the disease experienced local recurrence and had distant metastasis. In conclusion, EGFR positivity in pre -op biopsy samples seems to be associated with shorter survival, and increased EGFR expression in post -treatment resection specimens predicts aggressive behavior in patients with rectal adenocarcinoma who received NRT/NCRT. However, due to the molecular heterogeneity, EGFR expression status should be evaluated in resection specimens rather than in pre -op biopsy samples for optimal prognosis prediction.

Keywords

Author Keywords

Egfr adenocarcinoma prognosis neoadjuvant radiotherapy neoadjuvant chemoradiotherapy

Effect of Postoperative Adjuvant Radiotherapy on Quality of Life, Anxiety, and Depression in Adult Female Breast Cancer Patients

By

Parvizi, M (Parvizi, Murtaza) ; Kut, E (Kut, Engin) ; Akyol, M (Akyol, Murat) ; Ay, S (Ay, Semra)

 (provided by Clarivate) 

Source

CUREUS JOURNAL OF MEDICAL SCIENCE

Volume

15

Issue

3

DOI

10.7759/cureus.36635

Article Number

e36635

Published

MAR 24 2023

Indexed

2023-05-31

Document Type

Article

Abstract

Aim: This study aims to identify anxiety and depression caused by adjuvant radiotherapy in breast cancer cases to determine the deterioration in the quality of life and investigate the effect of early treatment. Materials and Methods: In this study, the Beck Depression Inventory, Beck Anxiety Inventory, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) Turkish 3.0 forms were evaluated in 63 breast cancer patients before the start of radiotherapy treatment (T1) and at six weeks after the end of radiotherapy treatment (T2). Results: A high level of anxiety was detected in 77.8% of patients, and depression was found in 25.4% of patients in T1. When depressive cases were evaluated with EORTC QLQ-C30 scores, the general health status (p = 0.043), role function (p = 0.027), emotional (p < 0.002), cognitive (p < 0.001), and social (p < 0.0001) scales were statistically lower in T1, whereas pain (p = 0.045) and insomnia (p < 0.0001) symptoms were higher in T1. Anxiety and EORTC QLQ-C30 scores in terms of emotional function (p = 0.015), social function (p < 0.003), and symptoms of insomnia (p = 0.027) were found to be statistically higher in T1 anxious cases. However, anxiety was detected in only 3% of T2 cases, and no depression was found in any of the cases. Anxiety and EORTC QLQ-C30 scores and symptom scales were evaluated in terms of role function (p < 0.0001), emotional (p = 0.041) and social scales (p = 0.014), fatigue (p = 0.028), pain (p = 0.033), insomnia (p = 0.011), and constipation (p < 0.0001); these were found to be statistically significant in T2. Conclusion: This study revealed that early diagnosis and treatment of anxiety before initiating adjuvant radiotherapy reduces the development of long-term anxiety-related depression in the future. Therefore, it is recommended that patients be evaluated for anxiety and depression before starting adjuvant radiotherapy.

Keywords

Author Keywords

beck depression inventory (bdi) beck anxiety inventoryeortc qlq-c30 psychiatric morbidity european organisation for research and treatment of cancer quality of life questionnaire-30 quality-of-life depression clinical anxietyradiotherapy (rt) breast cance

Evaluation of treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy accompanied by the G-8 geriatric score: TROD13-003 multicenter study

By

Güzelöz, Z (Guzeloz, Zeliha) ; Göken, LB (Gorken, lknur Bilkay) ; Aydin, B (Aydin, Barbaros) ; Sert, F (Sert, Fatma) ; Yalman, D (Yalman, Deniz) ; Parvizi, M (Parvizi, Murtaza) ; Avci, GG (Avci, Gulhan Guler) ; Altinok, P (Altinok, Pelin) ; Halis, H (Halis, Hatice) ; Ergen, SA (Ergen, Sefika Arzu) ; 

 (provided by Clarivate) 

Source

JOURNAL OF GERIATRIC ONCOLOGY

Volume

15

Issue

3

DOI

10.1016/j.jgo.2024.101739

Article Number

101739

Published

APR 2024

Early Access

MAR 2024

Indexed

2024-05-19

Document Type

Article

Abstract

Introduction: The choice of treatment for rectal cancer often differs in older and younger patients, with the rate of radiotherapy use lower among older adults. In our daily practice, when evaluating a frail older patient with rectal cancer, we usually choose to give less treatment. This may be due to concern that the patient will not be able to tolerate radiotherapy. The Geriatric 8 score (G8GS) is a guide to evaluating treatment tolerability as it relates to frailty in older adults with cancer. The aim of this study was to evaluate treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy (RT) accompanied by G8GS. Materials and Methods: Patients aged 65 and older with stage I-III rectal adenocarcinoma who were treated with RT and had a G8 evaluation were included in this multicenter retrospective study. Prognostic factors related to G8GS were calculated using Chi-square and logistic regression tests and survival rates were calculated by the Kaplan -Meier test using the SPSS v24.0 software. All p -values <= 0.05 were considered statistically significant. Results: A total of 699 patients from 16 national institutions were evaluated. The median age was 72 years (range 65 -96), and the median follow-up was 43 (range 1190) months. Four hundred and fifty patients (64%) were categorized as frail with G8GS <= 14 points. Frail patients had higher ages ( p = 0.001) and more comorbidities (p = 0.001). Ability to receive concomitant and/or adjuvant chemotherapy rates were significantly higher in fit patients ( p = 0.002 and p = 0.001, respectively). No significant difference was observed in terms of grade 3-4 early and late toxicity for both groups. Cancer-related death was higher ( p = 0.003), and 5and 8-year survival rates were significantly lower (p = 0.001), in the frail group. Age and being frail were significantly associated with survival. Discussion: Radiotherapy is a tolerable and effective treatment option for older adults with rectal cancer even with low G8GS. Being in the frail group according to G8GS and having multiple comorbidities was negatively associated with survival. Addressing the medical needs of frail patients through a comprehensive geriatric assessment prior to radiotherapy may improve G8GS, allowing for standard treatment and increased survival rates.

Keywords

Keywords Plus

ELDERLY-PATIENTS COLORECTAL-CANCER RADIATION-THERAPY SCREENING TOOLS PREOPERATIVE CHEMORADIOTHERAPY PROGNOSTIC VALUE RISK COMPLICATIONS CHEMOTHERAPY MANAGEMENT

Epidermal growth factor receptor expression and adjuvant chemoradiotherapy in rectal cancer Epidermal growth factor recepto in operated rectal cancer

By

Parvizi, M (Parvizi, Murtaza) ; Demir, D (Demir, Derya) ; Kut, E (Kut, Engin) ; Ergin, E (Ergin, Erhan) ; Ayhan, S (Ayhan, Semin) ; Doganavsargil, B (Doganavsargil, Basak)

 (provided by Clarivate) 

Source

ANNALS OF CLINICAL AND ANALYTICAL MEDICINE

Volume

14

Supplement

1

DOI

10.4328/ACAM.21649

Published

MAR 25 2023

Indexed

2023-04-19

Document Type

Article

Abstract

Aim: Epidermal Growth Factor Receptor (EGFR) is a trans-membrane protein with tyrosine kinase activity and is expressed in 25-80% of colon cancer cases. EFGR expression is prognostic in patients with metastatic colorectal cancer, and anti-EGR- based therapies are routinely used in the treatment of patients with metastatic colorectal cancer. To the best of our knowledge, the relationship between EGFR expression and prognosis in directly operated patients who did not receive neoadjuvant treatment and subsequently received chemo-radiotherapy is unknown. Therefore, we retrospectively evaluated patients with stage 3 rectal cancer who underwent surgery without any preoperative treatment in our center and aimed to investigate the relationship between EGFR expression and prognosis in patients who received adjuvant chemoradiotherapy.

Material and Methods: The data of patients who underwent surgery for rectal cancer and received chemoradiotherapy between 2010 and 2016 at Manisa State Hospital were retrospectively analyzed.

Results: According to EGFR expression, it was 127.01 (95% CI, 85.43-168.59) months in the group with 10% less staining and 47.44 (95% CI, 26.77-68.12) months in the group with 10% or more staining. Lymphovascular invasion (p=0.032), perineural invasion (p=0.023), histologic grade (p=0.004) and EGFR expression percentage (p=0.005) were significantly associated with survival in multivariate analyses

Discussion: The presence of 10% or more EGFR expression, LVI, PNI, and histological grade are significantly associated with survival in stage 3 rectal cancer patients who have undergone surgery and received postoperative chemotherapy. These markers can be used as prognostic biomarkers in the follow-up and treatment of these patients.

Keywords

Author Keywords

Epidermal Growth Factor Receptor Chemoradiotherapy Rectal Cancer Prognosis

Prognostic Significance of Hemoglobin/Prognostic Nutritional Index and Hemoglobin/Red Blood Cell Distribution in Rectal Cancer

By

Tuncel, ET (Tuncel, Elif Tugba) ; Parvizi, M (Parvizi, Murtaza) ; Kut, E (Kut, Engin) ; Aydin, M (Aydin, Mesut) ; Kasap, E (Kasap, Elmas)

 (provided by Clarivate) 

Source

TURKISH JOURNAL OF GASTROENTEROLOGY

Volume

34

Issue

2

Page

128-134

DOI

10.5152/tjg.2022.22203

Published

FEB 2023

Indexed

2023-04-10

Document Type

Article

Abstract

Background: We aimed to investigate the effect of hemoglobin/prognostic nutritional index and hemoglobin/red blood cell distribution, which are indicators of inflammation and nutrition, on prognosis and survival in patients with rectal cancer.

Methods: The retrospective study reviewed medical records of 138 patients with rectal cancer who were followed up between 2010 and 2021. The effects of hemoglobin/red blood cell distribution, hemoglobin/prognostic nutritional index, tumor stage, and lymph node status on survival and prognosis were evaluated using univariate and multivariate analyses. Overall survival and disease-free survival were calculated for both groups.

Results: Survival and prognosis were found to be significantly better in nonanemic patients with the hemoglobin/prognostic nutritional index higher than the cut-off value than in anemic patients with a normal or lower hemoglobin/prognostic nutritional index. Similarly, survival and prognosis were found to be significantly better in nonanemic patients with a hemoglobin/red blood cell distribution higher than the cut-off value than in anemic patients with a normal or lower hemoglobin/red blood cell distribution.

Conclusion: The results indicated that nutrition and inflammatory markers have independent prognostic significance in rectal cancer. These markers are simple, inexpensive, and useful biomarkers commonly used in clinical practice, and they were found to predict overall survival and disease-free survival independently.

Keywords

Author Keywords

H/PNI H/RDW nutritional status prognosis rectal cancer

Radiochemotherapy-related Lymphopenia in Head-and-Neck Cancer

By

Erdogan, M (Erdogan, Mihriban) ; Parvizi, M (Parvizi, Murtaza) ; Güzelöz, Z (Guzeloz, Zeliha)

 (provided by Clarivate) 

Source

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Volume

38

Issue

3

Page

382-391

DOI

10.5505/tjo.2023.4017

Published

2023

Early Access

SEP 2023

Indexed

2023-10-08

Document Type

Article

Abstract

OBJECTIVEThis study aimed to determine whether lymphopenia and neutrophil-to-lymphocyte ratio (NLR) could be prognostic factors of overall survival (OS), disease-free survival (DFS), or distant metastasis-free survival (DMFS) in patients with head-and-neck cancer (HNC) undergoing radical radiotherapy or chemoradiotherapy.METHODSEighty-four patients' medical records with HNC who underwent RT/conformal radiation therapy were retrospectively included in the study. Blood tests were analyzed at the treatment's beginning, middle, and end. The degree of lymphopenia was categorized according to the Common Terminology Criteria for Adverse Events. The OS, DFS, and DMFS were calculated with the Kaplan-Meier method. In addition, univariate and multivariate Cox regression analyses were used to investigate the relationship between lymphopenia and survival.RESULTSThe median follow-up time of patients was 20 months (range, 3-103). Forty-five deaths and a median 1-year OS of 76% were found. There was no difference in OS (median 27 months vs. 32 months, p=0.674) and DFS (30 months vs. 31 months, p=0.350) between patients who developed and did not develop lymphopenia during radiotherapy. However, survival was significantly worse in patients with G3 lymphopenia than in G1-2 patients (median 21 months vs. 49 months, p=0.033). When patients with an NLR of =4.9 and <4.9 were compared, no difference in OS (p=0.156) and DFS (p=0.830) was observed between these two groups. However, DMFS (43.1 months vs. 66.6 months, respectively, p=0.052) was worse in patients with high NLR (=4.9).CONCLUSIONTreatment-related G3 lymphopenia and high NLR rate are poor prognostic factors in patients with HNC.

Keywords

Author Keywords

Chemoradiot herapyhead and neck cancer lymphopenia neutrophil to lymphocyte ratio overall survival

Radiotherapy for benign diseases in Turkey: a patterns of care survey of the Turkish Society for Radiation Oncology (TROD 05-002)

By

Yildirim, HC (Yildirim, Halil Cumhur) ; Dinçbas, FÖ (Dincbas, Fazilet Oner) ; Demircan, V (Demircan, Volkan) ; Beyzadeoglu, M (Beyzadeoglu, Murat) ; Tekçe, E (Tekce, Ertugrul) ; Yazici, G (Yazici, Gozde) ; Turna, M (Turna, Menekse) ; Çetinayak, O (Cetinayak, Oguz) ; Baktir, KE (Baktir, Kudret Ensarioglu) ; Akin, M (Akin, Mustafa) ; 

 (provided by Clarivate) 

Source

STRAHLENTHERAPIE UND ONKOLOGIE

Volume

200

Issue

2

Page

143-150

DOI

10.1007/s00066-023-02154-x

Published

FEB 2024

Early Access

OCT 2023

Indexed

2024-02-24

Document Type

Article

Abstract

PurposeWe aimed to investigate the patterns of radiotherapy (RT) care in cases of benign diseases in Turkey.MethodsA questionnaire survey was sent to all radiation oncology (RO) departments in Turkey. The number of patients treated for benign disease between 2015 and 2020 was requested. A list of benign conditions was given, and information on the number of patients per disease, single and total doses prescribed, weekly fractions, radiation type, energy, and device was requested.ResultsOf the 138 RO departments, 29 (21%) responded. The data received concerned 15 (52%) university, 10 (34%) public, and four (14%) private hospitals. A total of 130,846 patients were treated with RT in these departments. Of these patients, 6346 (4.85%) were treated for benign conditions. The most common benign diseases treated with RT were meningioma (35%), plantar fasciitis (19%), schwannoma (16%), arteriovenous malformation (11%), and pituitary adenoma (7%). Most centers performed RT for paraganglioma, heterotopic ossification, vertebral hemangioma, and Graves' ophthalmopathy, but none treated arthrosis. Wide variations were observed across the departments. Radiosurgery for intracranial pathologies was performed intensively in four centers. By contrast, RT for plantar fasciitis was predominantly treated in five centers, one of which had more than 1000 patients.ConclusionThe ratio of patients who underwent RT for benign diseases in Turkey among all patients who underwent RT was 4.85%. The common pattern of RT in 72% of patients was radiosurgery for intracranial benign diseases, followed by low-dose RT for plantar fasciitis in 19%.

Keywords

Author Keywords

Radiation therapy Benign diseases Survey Hyperproliferative diseases Plantar fasciitis

A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001)

By

Yildirim, HC (Yildirim, Halil Cumhur) ; Kupik, GE (Kupik, Gulnihan Eren) ; Mustafayev, TZ (Mustafayev, Teuta Zoto) ; Berber, T (Berber, Tanju) ; Yavuz, B (Yavuz, Berrin) ; Cetinayak, O (Cetinayak, Oguz) ; Akagunduz, O (Akagunduz, Ozlem) ; Bicakci, BC (Bicakci, Beyhan Ceylaner) ; Arslan, SA (Arslan, Suheyla Aytac) ; Soykut, ED (Soykut, Ela Delikgoz) ; 

 (provided by Clarivate) 

Source

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Volume

45

Issue

5

Page

1194-1205

DOI

10.1002/hed.27333

Published

MAY 2023

Early Access

FEB 2023

Indexed

2023-03-22

Document Type

Article

Abstract

BackgroundWe aimed to evaluate patients with nasopharyngeal carcinoma (NPC) in a nonendemic population. MethodsIn a national, retrospective, multicenteric study, 563 patients treated with intensity modulated radiotherapy at 22 centers between 2015 and 2020 were analyzed. ResultsMedian age was 48 (9-83), age distribution was bimodal, 74.1% were male, and 78.7% were stage III-IVA. Keratinizing and undifferentiated carcinoma rates were 3.9% and 81.2%. Patients were treated with concomitant chemoradiotherapy (48.9%), or radiotherapy combined with induction chemotherapy (25%) or adjuvant chemotherapy (19.5%). After 34 (6-78) months follow-up, 8.2% locoregional and 8% distant relapse were observed. Three-year overall survival was 89.5% and was lower in patients with age >= 50, male sex, keratinizing histology, T4, N3 and advanced stage (III-IVA). ConclusionsPatients with NPC in Turkey have mixed clinical features of both east and west. Survival outcomes are comparable to other reported series; however, the rate of distant metastases seems to be lower.

Keywords

Author Keywords

Chemoradiotherapy EBV-DNA intensity-modulated radiotherapy nasopharyngeal carcinoma nonendemic

Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005)

By

Gul, SK (Gul, Sule Karabulut) ; Tepetam, H (Tepetam, Huseyin) ; Yildiz, F (Yildiz, Ferah) ; Er, I (Er, Ilhami) ; Oksuz, DC (Oksuz, Didem Colpan) ; Parvizi, M (Parvizi, Murtaza) ; Ozden, AS (Ozden, Ayse Sevgi) ; Alicikus, ZA (Alicikus, Zumre Arican) ; Sari, SY (Sari, Sezin Yuce) ; Alomari, O (Alomari, Omar) ; 

 (provided by Clarivate) 

Source

CLINICAL COLORECTAL CANCER

Volume

22

Issue

3

Page

318-326

DOI

10.1016/j.clcc.2023.05.004

Published

SEP 2023

Early Access

AUG 2023

Indexed

2023-10-02

Document Type

Article

Abstract

Study assessed 193 patients with anal canal cancer who received radiotherapy (RT) or radiochemotherapy in 11 centers in Turkey. Results showed that completing RT in < 45 days and concurrent chemotherapy improved survival. Higher treatment doses and IMRT were found to have lower side effects and better survival. Findings suggest radiochemotherapy remains main treatment, advanced RT techniques may increase survival, and results are significant for improving anal canal cancer treatment.Background and Aim: This study aimed to determine treatment outcomes and factors affecting prognosis in patients diagnosed with anal canal cancer who received radical radiotherapy (RT) or radiotherapy combined with chemotherapy (CT-RT) in radiation oncology centers in Turkey and compare the results with literature. Material and Method: The study included 193 patients with anal canal cancer reported between 1995 and 2019, of which 162 had complete data. The study was conducted in 11 radiation oncology centers, and a joint database was shared among them. Patients received radiotherapy doses of 45 Gy to 60 Gy. Data analysis was done using SPSS for Windows version 20. Results: Median follow-up was 48.51 months (2-214). All patients received radiotherapy, and 140 (86.4%) received concurrent chemotherapy. Radiotherapy doses of 50.4 Gy to 60 Gy were administered to 74 patients (45.7%) using 2-dimensional 3-dimensional (2D-3D) conformal therapy and 70 patients (43.2%) using intensity modulated radiotherapy technique (IMRT). Acute phase hematologic toxicity was observed in 62 patients (38.3%), and nonhematologic toxicity in 123 patients (75.9%). The 5-year overall survival (OS) rate was 75.1% and disease-specific survival (DSS) rate was 76.4%. OS without colostomy was achieved in 79,8 % at 5 years, and complete response in 112 patients (69.1%). OS rate was significantly higher in 142 patients with positive response ( P < .000) and 112 with complete response ( P < .000). Anemia ( P < .002), local progression, and systemic progression ( P < .000) resulted in lower OS ( P < .002). In univariate analysis, factors affecting OS rate were: gender, age, stage, lymph node status, T stage, RT treatment duration, and treatment planning with PET fusion, which were found to be statistically significant. Completing radiotherapy in less than 45 days, concurrent chemotherapy, and continued administration of mitomycin and 5 FU as chemotherapy had a significant positive effect on overall survival. OS rate was higher in patients receiving RT dose of 58 Gy or less and undergoing IMRT planning in radiotherapy. IMRT was associated with lower acute and late side effects. Conclusion: Radiochemotherapy is the primary treatment for anal canal cancer and advanced radiotherapy techniques may increase survival by reducing side effects and improving treatment continuation. Higher treatment doses require further investigation. The efficacy of treatment can be improved by including patients treated with modern radiotherapy techniques in multicenter prospective studies using new and more effective chemotherapy and immunotherapy agents.

Keywords

Author Keywords

IMRT HIV HPV Mitomycin5- Fluorouracil

An analysis of adjuvant treatment strategies in operated pancreatic cancer patients: An Izmir oncology group study

By

Varol, U (Varol, Umut) ; Uzum, Y (Uzum, Yusuf) ; Sengul, A (Sengul, Adem) ; Korkmaz, U (Korkmaz, Ugur) ; Parvizi, M (Parvizi, Murtaza) ; Akyol, M (Akyol, Murat) ; Taskaynatan, H (Taskaynatan, Halil) ; Salman, T (Salman, Tarik) ; Oflazoglu, U (Oflazoglu, Utku) ; Yildiz, Y (Yildiz, Yasar) ; 

 (provided by Clarivate) 

Source

INDIAN JOURNAL OF CANCER

Volume

57

Issue

2

Page

158-163

DOI

10.4103/ijc.IJC_318_18

Published

APR-JUN 2020

Indexed

2020-06-15

Document Type

Review

Abstract

Background: Adjuvant treatment is necessary in pancreatic cancer patients, but the optimal approach is not clear yet. Our aim was to explore the effectiveness of adjuvant treatment modalities in patients with operated pancreatic cancer. Methods: There were five groups of patients operated for primary pancreas adenocarcinoma. The first two groups included patients who were treated with only adjuvant chemotherapy or radiotherapy. The patients in third group had received combination chemotherapy and radiotherapy either sequentially or concomitantly. The fourth group was composed of patients who were treated with adjuvant chemotherapy after concurrent chemoradiotherapy, whereas the patients in the fifth group were only observed after surgery without any adjuvant treatment. Results: There were 83 operated pancreatic cancer patients available for analysis. Median age of the patients was 63 years (range, 40-82 years). There were 55 patients who had local disease recurrence (n = 14) or metastasis (n = 41) during or after adjuvant treatment. The median overall survival for all patients was 14 months. When we compared the median survival of patients who had any adjuvant treatment with the patients treated without any adjuvant therapy, we found a significant statistical difference between the groups (32.4 vs 6.5 months; P = 0.000). In addition, survival of each treatment group was also compared with each other but we did not find any significant statistical difference. Conclusions: Our result suggests that any adjuvant therapy in the treatment of pancreatic cancer patients is important. However, we could not find any superiority between adjuvant treatment modalities.

Keywords

Author Keywords

Adjuvant pancreatic cancer treatment

Effect of delayed radical cystectomy for invasive bladder tumors on lymph node positivity, cancer-specific survival and total survival

By

Türk, H (Turk, Hakan) ; Ün, S (Un, Sitki) ; Cinkaya, A (Cinkaya, Ahmet) ; Kodaz, H (Kodaz, Hilmi) ; Parvizi, M (Parvizi, Murtaza) ; Zorlu, F (Zorlu, Ferruh)

 (provided by Clarivate) 

Source

TUMORI JOURNAL

Volume

104

Issue

6

Page

434-437

DOI

10.5301/tj.5000626

Published

DEC 2018

Indexed

2019-01-11

Document Type

Article

Abstract

Introduction: Radical cystectomy (RC) is the main treatment option for patients with muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), which carry the highest risk of progression. In this study, we investigated the effect of time from transurethral resection of the bladder (TUR-B) to cystectomy on lymph node positivity, cancer-specific survival and overall survival in patients with MIBC. Methods: The records were reviewed of 530 consecutive patients who had RC and pelvic lymphadenectomy procedures with curative intent performed by selected surgeons between May 2005 and April 2016. Our analysis included only patients with transitional cell carcinoma of the bladder; we excluded 23 patients with other types of tumor histology. Results: Patients who underwent delayed RC were compared with patients who were treated with early RC; both groups were similar in terms of age, gender, T stage, tumor grade, tumor differentiation, lymph node status and metastasis status. However, when both groups were compared for disease-free survival and overall survival, patients of the early-RC group had a greater advantage. Conclusions: The optimal time between the last TUR-B and RC is still controversial. A reasonable time for preoperative preparation can be allowed, but long delays, especially those exceeding 3 months, can lead to unfavorable outcomes in cancer control.